BioCentury | May 6, 2019
Distillery Therapeutics

The GJA1 inhibitor clofazimine to treat glioblastoma

...blood-brain barrier (BBB) penetration. Novartis AG has clofazimine (LAM320) in Phase III testing for tuberculosis. CoDa Therapeutics Inc....
BioCentury | Jan 14, 2016
Distillery Therapeutics

Therapeutics: Gap junction protein α 1, 43kDa (GJA1; CX43; connexin-43)

...steps include optimizing the combined delivery of the GJA1 inhibitor and temozolomide to the brain. CoDa Therapeutics Inc....
BioCentury | Jul 24, 2014
Cover Story

It is an RNA world

...RNAi therapeutic Phase II Topical on skin CoDa Therapeutics Inc....
...IRS1) mRNA Phase III Corneal epithelial defects CoDa Therapeutics Inc....
BioCentury | Jan 21, 2013
Clinical News

Nexagon: Phase IIb data

...data support advancing Nexagon into Phase III testing, but could not be reached for details. CoDa Therapeutics Inc....
BioCentury | Jul 30, 2012
Financial News

CoDa Therapeutics financial update

...participated in the close. CoDa raised $19.4 million in a first close in April 2011. CoDa Therapeutics Inc....
BioCentury | Feb 2, 2012
Targets & Mechanisms

Closing the gap on liver toxicity

...data "raise some questions about the specificity of 2APB," said Anthony Phillips, medical director of CoDa Therapeutics Inc....
...Fulmer, T. SciBX 5 (5); doi:10.1038/scibx.2012.115 Published online Feb. 2, 2012 Companies and Institutions Mentioned CoDa Therapeutics Inc....
BioCentury | Oct 17, 2011
Financial News

CoDa Therapeutics financial update

...Coda secured a $6 million credit facility with Square 1 Bank. CoDa Therapeutics Inc. , San Diego, Calif...
BioCentury | May 9, 2011
Company News

CoDa Therapeutics management update

CoDa Therapeutics Inc. , San Diego, Calif. Business: Dermatology, Ophthalmic Hired: David Eisenbud as CMO, formerly medical director of the Overlook Hospital Wound Healing Program and managing partner at Millburn Surgical Associates WIR Staff Dermatology Ophthalmic...
BioCentury | May 2, 2011
Finance

Anti-anti-wound healing

...wound healing programs is money wasted, but a trio of investors is doubling down on CoDa Therapeutics Inc....
BioCentury | Apr 25, 2011
Financial News

CoDa Therapeutics completes venture financing

CoDa Therapeutics Inc. , San Diego, Calif. Business: Dermatology, Ophthalmic Date completed: 4/18/11 Type: Venture financing Raised: $19.2 million Investors: Domain Associates; GBS Venture Partners; BioPacificVentures Note: CoDa said it plans to raise a further $10-$15...
Items per page:
1 - 10 of 15
BioCentury | May 6, 2019
Distillery Therapeutics

The GJA1 inhibitor clofazimine to treat glioblastoma

...blood-brain barrier (BBB) penetration. Novartis AG has clofazimine (LAM320) in Phase III testing for tuberculosis. CoDa Therapeutics Inc....
BioCentury | Jan 14, 2016
Distillery Therapeutics

Therapeutics: Gap junction protein α 1, 43kDa (GJA1; CX43; connexin-43)

...steps include optimizing the combined delivery of the GJA1 inhibitor and temozolomide to the brain. CoDa Therapeutics Inc....
BioCentury | Jul 24, 2014
Cover Story

It is an RNA world

...RNAi therapeutic Phase II Topical on skin CoDa Therapeutics Inc....
...IRS1) mRNA Phase III Corneal epithelial defects CoDa Therapeutics Inc....
BioCentury | Jan 21, 2013
Clinical News

Nexagon: Phase IIb data

...data support advancing Nexagon into Phase III testing, but could not be reached for details. CoDa Therapeutics Inc....
BioCentury | Jul 30, 2012
Financial News

CoDa Therapeutics financial update

...participated in the close. CoDa raised $19.4 million in a first close in April 2011. CoDa Therapeutics Inc....
BioCentury | Feb 2, 2012
Targets & Mechanisms

Closing the gap on liver toxicity

...data "raise some questions about the specificity of 2APB," said Anthony Phillips, medical director of CoDa Therapeutics Inc....
...Fulmer, T. SciBX 5 (5); doi:10.1038/scibx.2012.115 Published online Feb. 2, 2012 Companies and Institutions Mentioned CoDa Therapeutics Inc....
BioCentury | Oct 17, 2011
Financial News

CoDa Therapeutics financial update

...Coda secured a $6 million credit facility with Square 1 Bank. CoDa Therapeutics Inc. , San Diego, Calif...
BioCentury | May 9, 2011
Company News

CoDa Therapeutics management update

CoDa Therapeutics Inc. , San Diego, Calif. Business: Dermatology, Ophthalmic Hired: David Eisenbud as CMO, formerly medical director of the Overlook Hospital Wound Healing Program and managing partner at Millburn Surgical Associates WIR Staff Dermatology Ophthalmic...
BioCentury | May 2, 2011
Finance

Anti-anti-wound healing

...wound healing programs is money wasted, but a trio of investors is doubling down on CoDa Therapeutics Inc....
BioCentury | Apr 25, 2011
Financial News

CoDa Therapeutics completes venture financing

CoDa Therapeutics Inc. , San Diego, Calif. Business: Dermatology, Ophthalmic Date completed: 4/18/11 Type: Venture financing Raised: $19.2 million Investors: Domain Associates; GBS Venture Partners; BioPacificVentures Note: CoDa said it plans to raise a further $10-$15...
Items per page:
1 - 10 of 15